Literature DB >> 17341419

Alendronate induces anti-migratory effects and inhibition of neutral phosphatases in UMR106 osteosarcoma cells.

M Silvina Molinuevo1, Liliana Bruzzone, Ana M Cortizo.   

Abstract

Bisphosphonates are nonhydrolysable pyrophosphate analogues that prevent bone loss in several types of cancer. However, the mechanisms of anticancer action of bisphosphonates are not completely known. We have previously shown that nitrogen-containing bisphosphonates directly inhibit alkaline phosphatase of UMR106 rat osteosarcoma cells. In this study, we evaluated the effects of alendronate on the migration of UMR106 osteosarcoma using a model of multicellular cell spheroids, as well as the alendronate effect on neutral phosphatases. Alendronate significantly inhibited the migration of osteoblasts in a dose-dependent manner (10(-6)-10(-4) M). This effect was also dependent on calcium availability. The spheroid morphology and distribution of actin fibers were also affected by alendronate treatment. Alendronate dose-dependently inhibited neutral phosphatase activity in cell-free osteoblastic extracts as well as in osteoblasts in culture. Our results show that alendronate inhibits cell migration through mechanisms dependent on calcium, and that seem to involve inhibition of phosphotyrosine-neutral-phosphatases and disassembly of actin stress fibers.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17341419     DOI: 10.1016/j.ejphar.2007.01.054

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  5 in total

1.  Addition of pamidronate to chemotherapy for the treatment of osteosarcoma.

Authors:  Paul A Meyers; John H Healey; Alexander J Chou; Leonard H Wexler; Pamela R Merola; Carol D Morris; Michael P Laquaglia; Michael G Kellick; Sara J Abramson; Richard Gorlick
Journal:  Cancer       Date:  2010-11-08       Impact factor: 6.860

2.  The Current and Future Therapies for Human Osteosarcoma.

Authors:  Joseph D Lamplot; Sahitya Denduluri; Jiaqiang Qin; Ruidong Li; Xing Liu; Hongyu Zhang; Xiang Chen; Ning Wang; Abdullah Pratt; Wei Shui; Xiaoji Luo; Guoxin Nan; Zhong-Liang Deng; Jinyong Luo; Rex C Haydon; Tong-Chuan He; Hue H Luu
Journal:  Curr Cancer Ther Rev       Date:  2013-02

3.  Alendronate Functionalized Mesoporous Bioactive Glass Nanospheres.

Authors:  Elisa Boanini; Silvia Panseri; Fabiola Arroyo; Monica Montesi; Katia Rubini; Anna Tampieri; Cristian Covarrubias; Adriana Bigi
Journal:  Materials (Basel)       Date:  2016-02-26       Impact factor: 3.623

4.  Inhibition of growth and migration of cholangiocarcinoma cells by pamidronate.

Authors:  Benjaporn Buranrat; Auemduan Prawan; Laddawan Senggunprai; Veerapol Kukongviriyapan
Journal:  Exp Ther Med       Date:  2019-09-23       Impact factor: 2.447

5.  Targeting angiogenesis-dependent calcified neoplasms using combined polymer therapeutics.

Authors:  Ehud Segal; Huaizhong Pan; Paula Ofek; Taturo Udagawa; Pavla Kopecková; Jindrich Kopecek; Ronit Satchi-Fainaro
Journal:  PLoS One       Date:  2009-04-21       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.